Jump to content

Talk:Genome editing

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Wiki Education Foundation-supported course assignment

[edit]

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Jez.chow. Peer reviewers: Richard.arnold32.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 21:43, 17 January 2022 (UTC)[reply]

Wiki Education Foundation-supported course assignment

[edit]

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Hatonya.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 21:43, 17 January 2022 (UTC)[reply]

Wiki Education Foundation-supported course assignment

[edit]

This article was the subject of a Wiki Education Foundation-supported course assignment, between 27 August 2018 and 8 December 2018. Further details are available on the course page. Student editor(s): Gaellemardy.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 21:43, 17 January 2022 (UTC)[reply]

Techniques

[edit]

sorry, but why is the "recombinant Adeno-Associated Virus (rAAV)" approach not mentioned in the article?

according to " http://www.labnews.co.uk/features/the-importance-of-gene-editing/ " this non-pathogenic single stranded DNA-virus [...] has a unique and powerful capability to induce HR at rates of around 1,000 times greater than seen using simple double stranded DNA vectors. rAAV vectors are engineered to contain a single stranded DNA ‘replacement’ genome that is substantially homologous to the target gene of interest and can therefore act as a template for HR

The alternative template DNA could contain any of the full range of genetic alterations (small or large gene deletions, point-mutations, reversion of mutations to wild-type, translocations, amplifications and transgene insertions), and these will be incorporated into the cell’s genome with unparalleled precision. As the vectors do not contain any viral genes, no viral genes will be co-inserted. Though there is some potential for random integration, this is minimal so most mutations are generated without introducing unwanted and confounding genotypes and/or phenotypes.

  • note that the article tauts that the "random integration [...] is minimal" but not citations are given (throughout the article), and
  • note also that the article blasts the ZFNs and TALENS for serious problems with "off-target modifications".
  • the article needs a dedicated, seriously quantitative section on the rate of "off-target modifications" per megabase or genome, for each method and several model-organism genomes.

keep the great work!  :) — Preceding unsigned comment added by Marcos.alberto (talkcontribs) 14:26, 18 April 2013 (UTC)[reply]

Sources

[edit]

I've just added these two reviews to support the lead paragraph. However, I think there's a lot more content in this article that they could be used for, so I'm leaving this note here for anyone who wants to help.

  • Esvelt, KM.; Wang, HH. (2013). "Genome-scale engineering for systems and synthetic biology". Mol Syst Biol. 9: 641. doi:10.1038/msb.2012.66. PMID 23340847. {{cite journal}}: Cite has empty unknown parameter: |month= (help)
  • Tan, WS.; Carlson, DF.; Walton, MW.; Fahrenkrug, SC.; Hackett, PB. (2012). "Precision editing of large animal genomes". Adv Genet. 80: 37–97. doi:10.1016/B978-0-12-404742-6.00002-8. PMID 23084873. {{cite journal}}: Cite has empty unknown parameter: |month= (help)

--Arc de Ciel (talk) 07:19, 20 July 2013 (UTC)[reply]

CRISPR

[edit]

I suggest to change the term CRISPR to CRISPR/Cas in the following sentence: "There are currently four families of engineered nucleases being used: Zinc finger nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), CRISPR, and engineered meganuclease re-engineered homing endonucleases."

Because CRISPR refers to the origin of the guiding RNA sequences (or to this type of bacterial immune system) but CRISPR is actually not the nuclease. The nuclease is called Cas.

references e.g.: "DNA targeting specificity of RNA-guided Cas9 nucleases" Nature Biotechnology 31, 827–832 (2013) http://www.nature.com/nbt/journal/v31/n9/full/nbt.2647.html

or

"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Science. 2012 Aug 17;337(6096):816-21 http://www.sciencemag.org/content/337/6096/816.short --N1K0W1N (talk) 19:00, 15 December 2013 (UTC)[reply]

[edit]

In the first section of this article CRISPR/Cas9 is brought us as a breakthrough in genome editing. The reader should have the ability to the click on CRISPR and be brought to the wikipedia page to learn more about what it is. If there is no link than this should be its own short section or have a description of CRISPR added to the gene therapy section. Kputnam28 (talk) 05:17, 12 February 2016 (UTC)[reply]

COI

[edit]

COI concerns have been raised w.r.t. Genome editing (and other articles - see Wikipedia:Conflict_of_interest/Noticeboard#Cellectis). It would be well for a neutral and informed editor to review this edit, from a user with declared COI acting on behalf of Cellectis, a company which has an interest in Meganuclease. --Tagishsimon (talk) 17:18, 18 March 2016 (UTC)[reply]

COI review

[edit]
I've finally got around to reviewing this page for COI and NPOV issues (apologies for the delay). The edits added by Dcbennett2 are a mix of uncontroversial wording copyedits and additional information on TALENs. The TALEN additions are accurate, and don't throw the article's balance out. The TM issue has already been fixed by other editors. Some language was a little editorial (though not a really a COI issue). "One avenue of exciting research involves..." is unnecessary, and "Physicians at the Great Ormond Street Hospital recently announced the first clinical use of TALEN-based genome editing..." should just be "The first clinical use of TALEN-based genome editing was...". T.Shafee(Evo﹠Evo)talk 12:48, 10 April 2016 (UTC)[reply]

General review

[edit]

As a separate issue the article as a whole still needs some work:

  • There are multiple sections with 'recent' examples from 5 years ago
  • The Prospects and limitations section is over-focussed on ZFNs and or a fast moving area will go out of date within a couple of years of writing
  • The Concept section should be split into Concepts (common principles) and Methods (specific techniques, e.g. ZFN, TALEN, CRISPR)
  • I'm doubtful that the Applications section gives a balanced overview of the main current applications of the technologies
  • The article probably needs a separate History section to put the significance of the general field modern methods in context
  • It should be checked is the current spread of example uses is a fair coverage of the most common/significant works.

There are plenty of good academic reviews out there, so it'd be good to try to get this article up to at least B class. I'm happy to have a go at some of it but I'd gladly welcome help. T.Shafee(Evo﹠Evo)talk 12:54, 10 April 2016 (UTC)[reply]

Update please

[edit]

Homology-independent targeted integration (HITI)


Wiki Education assignment: Technology and Culture

[edit]

This article was the subject of a Wiki Education Foundation-supported course assignment, between 21 August 2023 and 15 December 2023. Further details are available on the course page. Peer reviewers: MatthieuFoucu.

— Assignment last updated by Thecanyon (talk) 05:33, 12 December 2023 (UTC)[reply]